Raltegravir-Intensified ART: More Rapid Declines in HIV Viral Load But No Impact On IRIS
March 12th 2018Raltegravir-intensified therapy resulted in significantly faster viral load declines in HIV-infected adults and older children but did not reduce overall mortality or WHO 3/4 events compared with standard triple-drug ART.
New Clinical Trials To Test Monoclonal Antibodies for Prevention of Widespread Bacterial Infections
March 9th 2018The Antibacterial Resistance Leadership Group (ARLG) is working to enroll patients in clinical trials of 2 investigational monoclonal antibodies, with the ultimate goal of reducing antimicrobial resistance.
Assessing Interest in New Antiretroviral Therapies May Help Inform Uptake & Adherence
March 8th 2018In an oral abstract session at CROI 2018, Dr. Nathan Thielman stresses that understanding the interest of HIV-positive treatment-experienced individuals in new antiretroviral therapies may help inform their development and uptake.